Search

Your search keyword '"Oxides pharmacology"' showing total 78 results

Search Constraints

Start Over You searched for: Descriptor "Oxides pharmacology" Remove constraint Descriptor: "Oxides pharmacology" Publisher blackwell scientific publications Remove constraint Publisher: blackwell scientific publications
78 results on '"Oxides pharmacology"'

Search Results

1. Antibacterial, biocompatible, and mineralization-inducing properties of calcium silicate-based cements.

2. The toxicity of chlorine dioxide to clownfish and its bactericidal capability to pathogenic strains of vibrio spp.

3. Biocompatibility and bioactive potential of NeoPUTTY calcium silicate-based cement: An in vivo study in rats.

4. Inflammatory response and odontogenic differentiation of inflamed dental pulp treated with different pulp capping materials: An in vivo study.

5. Cytotoxicity, biocompatibility and osteoinductive profile of an MTA-hydrogel-based cement: An in vitro and animal study.

6. Inflammatory and differentiation cellular response to calcium silicate cements: An in vitro study.

7. Participation of fibroblast growth factor-1 and interleukin-10 in connective tissue repair following subcutaneous implantation of bioceramic materials in rats.

8. Biocompatibility and bioactive potential of an experimental tricalcium silicate-based cement in comparison with Bio-C repair and MTA Repair HP materials.

9. Concentrated MTA Repair HP reduced biofilm and can cause reparative action at a distance.

10. The molecular functions of Biodentine and mineral trioxide aggregate in lipopolysaccharide-induced inflamed dental pulp cells.

11. Biocompatibility of mineral trioxide aggregate flow and biodentine.

12. Mast cells and immunoexpression of FGF-1 and Ki-67 in rat subcutaneous tissue following the implantation of Biodentine and MTA Angelus.

13. Detection of bone marrow-derived fibrocytes in human dental pulp repair.

14. Cytokine expression in response to root repair agents.

15. Evaluation of the bioactivity of fluoride-enriched mineral trioxide aggregate on osteoblasts.

16. Effect of root canal irrigation protocols on the dislocation resistance of mineral trioxide aggregate-based materials: A systematic review of laboratory studies.

17. The effect of accelerated mineral trioxide aggregate on odontoblastic differentiation in dental pulp stem cell niches.

18. RUNX-2, OPN and OCN expression induced by grey and white mineral trioxide aggregate in normal and hypertensive rats.

19. Effect of MTA particle size on periapical healing.

20. Bioactivity and biomineralization ability of calcium silicate-based pulp-capping materials after subcutaneous implantation.

21. Comparative analysis of the biological effects of the endodontic bioactive cements MTA-Angelus, MTA Repair HP and NeoMTA Plus on human dental pulp stem cells.

22. An assessment of the overexpression of BMP-2 in transfected human osteoblast cells stimulated by mineral trioxide aggregate and Biodentine.

23. Biocompatibility and mineralized nodule formation of Neo MTA Plus and an experimental tricalcium silicate cement containing tantalum oxide.

24. Zirconium oxide and niobium oxide used as radiopacifiers in a calcium silicate-based material stimulate fibroblast proliferation and collagen formation.

25. Cytotoxicity and bioactivity of various pulpotomy materials on stem cells from human exfoliated primary teeth.

26. MTA-induced Notch activation enhances the proliferation of human dental pulp cells by inhibiting autophagic flux.

27. Human dental pulp cells response to mineral trioxide aggregate (MTA) and MTA Plus: cytotoxicity and gene expression analysis.

28. Osteogenic cell response to calcium aluminate-based cement.

29. Expression of KLF5 in odontoblastic differentiation of dental pulp cells during in vitro odontoblastic induction and in vivo dental repair.

30. Effects of a novel light-curable material on odontoblastic differentiation of human dental pulp cells.

31. Bioactivity of MTA Plus, Biodentine and an experimental calcium silicate-based cement on human osteoblast-like cells.

32. Cytocompatibility of Biodentine using a three-dimensional cell culture model.

33. Comparison of in vivo dental pulp responses to capping with iRoot BP Plus and mineral trioxide aggregate.

34. In vivo evaluation of the inflammatory response and IL-6 immunoexpression promoted by Biodentine and MTA Angelus.

35. Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.

36. Effect of BioAggregate on osteoclast differentiation and inflammatory bone resorption in vivo.

37. Role of the p38 pathway in mineral trioxide aggregate-induced cell viability and angiogenesis-related proteins of dental pulp cell in vitro.

38. Comparative cell attachment, cytotoxicity and antibacterial activity of radiopaque dicalcium silicate cement and white-coloured mineral trioxide aggregate.

39. Effect of Biodentine and Bioaggregate on odontoblastic differentiation via mitogen-activated protein kinase pathway in human dental pulp cells.

40. The synergistic effects of fibroblast growth factor-2 and mineral trioxide aggregate on an osteogenic accelerator in vitro.

41. Bioactivity evaluation of three calcium silicate-based endodontic materials.

42. Antibiofilm activity, pH and solubility of endodontic sealers.

43. The response of cementoblasts to calcium phosphate resin-based and calcium silicate-based commercial sealers.

44. Cytocompatibility of the ready-to-use bioceramic putty repair cement iRoot BP Plus with primary human osteoblasts.

45. Biodentine(TM) induces TGF-β1 release from human pulp cells and early dental pulp mineralization.

46. Antibacterial activity of two MTA-based root canal sealers.

47. A histological study of pulp reaction to various water/powder ratios of white mineral trioxide aggregate as pulp-capping material in human teeth: a double-blinded, randomized controlled trial.

48. Human dental pulp cell responses to new calcium silicate-based endodontic materials.

49. Histological and histomorphometrical evaluation of furcation perforations filled with MTA, CPM and ZOE.

50. microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells.

Catalog

Books, media, physical & digital resources